Last edition
News about "Takeda "
BridGene Biosciences Signs Deal with Takeda to Discover Small Molecule Drugs
Under the terms of the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against challenging targets in immunology and neurology.
Takeda | 26/02/2025 | By Aishwarya
Halozyme Announces Takeda Gets Approval for HYQVIA with ENHANZE in Japan
HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10 percent and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE drug delivery technology.
Takeda | 31/12/2024 | By Aishwarya
Lupin and Takeda to Commercialize Vonoprazan in India
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.
Takeda | 19/09/2024 | By Aishwarya | 212
Mankind Pharma Signs License Deal with Takeda to Commercialise Acidity Drug in India
Mankind Pharma has signed a non-exclusive patent licence agreement with Takeda Pharmaceuticals for commercialising acidity drug Vonoprazan in the Indian market.
Takeda | 22/07/2024 | By Aishwarya | 176
Takeda Signs Option Deal with Ascentage Pharma to Get Exclusive Global License for Olverembatinib
Takeda has signed an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor.
Takeda | 15/06/2024 | By Aishwarya | 166
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy